ArticleFrontiers in pharmacology2025
Patient-derived organoids reveal marked heterogeneity in chemosensitivity profiles of colorectal cancer and a potential association with HER2 status.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Single-cell analysis identifies a stemness-associated tumor cell subpopulation and develops a prognostic scoring model in esophageal squamous cell carcinoma.Translational oncology · 2026Article
- Gut microbiota-mediated chemotherapy resistance in colorectal cancer: mechanisms and precision interventions.Frontiers in oncology · 2026Review
- EGFR-targeted affibody-polyIC polyplex kills EGFR-overexpressing cancer cells without activating the EGFR.PloS one · 2026Article
- The application of organoids in treatment decision-making for digestive system cancers: progress and challenges.Molecular cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the sensitivity and heterogeneity of standard first-line chemotherapy regimens for colorectal cancer (CRC) using patient-derived tumor organoids (PDTOs). Drug sensitivity testing in 15 CRC PDTOs revealed varying proportions of samples classified as sensitive (inhibition rate >50%) across different regimens: FOLFIRI (60%), FOLFOX (40%), CAPEOX (26.7%), and 5-Fluorouracil (26.7%). Furthermore, exploratory analysis indicated that for FOLFIRI and FOLFOX regimens, HER2(1+) status was significantly associated with lower inhibition grades compared to HER2(0) status (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.